Abstract
The aim of this study was to test genetic differences in the clinical response to rizatriptan in patients affected by migraine without aura. These genetic differences could be explained by various genes, the HTR1B, encoding the 5-HT1 receptor subtype, MAOA gene that encodes the monoamino-oxidase, the main metabolic enzyme of this triptan, SLC6A4 (gene encoding the serotonin transporter) and DRD2 (gene encoding the D2 receptor), both involved in the pathogenesis of migraine. Fifty unrelated patients affected by migraine without aura (IHS) were included. Patients were divided into two groups (responders and non-responders) according to clinical response. Thirty-one out of fifty patients responded to rizatriptan. A significant difference among the two groups was observed in both allele (p=0.02) and genotype distribution (p=0.03) of DRD2/NcoI. The significant association with the DRD2/NcoI polymorphism in responders suggested that the DRD2/NcoI C allele may be considered a susceptibility factor heralding a good response to rizatriptan.
Article PDF
Similar content being viewed by others
References
Visser WH, Burggraaf J, Muller LM et al (1996) Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 60:452–460, 10.1016/S0009-9236(96)90202-7, 1:CAS:528:DyaK28XmvFWku7s%3D, 8873693
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668–1675, 10.1016/S0140-6736(01)06711-3, 1:CAS:528:DC%2BD3MXos1ajsro%3D, 11728541
Waeber C, Moskowitz MA (2003) Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 61[Suppl 4]:S9–S20, 14581653
Maassen VanDenBrink A, Van Den Broek RWM, De Vries R et al (2000) Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55:1524–1530, 1:STN:280:DC%2BD3M%2FmvFKmsw%3D%3D
Peroutka SJ (1997) Dopamine and migraine. Neurology 49:650–656, 1:CAS:528:DyaK2sXmtlOntb8%3D, 9305317
Peroutka SJ, Wilholt T, Jones K (1997) Clinical susceptibility in migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology 49:201–206, 1:CAS:528:DyaK2sXkvFems78%3D, 9222191
Del Zompo M, Cherchi A, Palmas MA et al (1998) Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 51:781–786, 9748026
Mathew NT, Kailasam J, Gentry P, Chernyshev O (2000) Treatment on nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trials. Headache 40:464–465, 10.1046/j.1526-4610.2000.00069.x, 1:STN:280:DC%2BD3cvht1OrtQ%3D%3D, 10849042
Sarkar G, Kapelner S, Grandy DK et al (1991) Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptor. Genomics 11:8–14, 10.1016/0888-7543(91)90096-W, 1:CAS:528:DyaK38XksFyl, 1837284
Arinami T, Gao M, Hamaguchi H, Toru M (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associate with schizophrenia. Hum Mol Genet 6:577–582, 10.1093/hmg/6.4.577, 1:CAS:528:DyaK2sXisFOku7Y%3D, 9097961
Lesch KP, Bengel D, Heils A et al (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527–1531, 10.1126/science.274.5292.1527, 1:CAS:528:DyaK28Xnt1ansL8%3D, 8929413
Lappalainen J, Dean M, Charbonneau L et al (1995) Mapping of serotonin 5-HT1D, autoreceptor gene on chromosome 6 and direct analysis for sequence variants. Am J Med Genet 60:157–161, 10.1002/ajmg.1320600214, 1:STN:280:DyaK28%2FptVagtA%3D%3D, 7485252
Hotamisligil GS, Breakefield XO (1991) Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet 49:383–392, 1:CAS:528:DyaK3MXmsV2hurw%3D, 1678250
Ott J (1999) Analysis of human genetic linkage. Johns Hopkins University Press, Baltimore
Sham PC, Curtis D (1995) Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59:97–105, 10.1111/j.1469-1809.1995.tb01608.x, 1:STN:280:DyaK2M3otlansg%3D%3D, 7762987
Maassen VanDenBrink A, Vergouwe MN, Ophoff RA et al (1998) 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache 38:288–291, 10.1046/j.1526-4610.1998.3804288.x, 1:STN:280:DyaK1c3lvVagsA%3D%3D
Maassen VanDenBrink A, Vergouwe MN, Ophoff RA et al (1998) Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet 77:415–420, 10.1002/(SICI)1096-8628(19980605)77:5<415::AID-AJMG12>3.0.CO;2-L, 1:STN:280:DyaK1c3ptl2lsA%3D%3D, 9632173
Ophoff RA, Van Den Maagdenberg A, Roon KI et al (2001) The impact of pharmacogenetics for migraine. Eur J Pharmacol 413:1–10, 10.1016/S0014-2999(00)00949-3, 1:CAS:528:DC%2BD3MXhtFensrs%3D, 11173058
Iadecola C (1998) Neurogenic control of the cerebral circulation: is dopamine minding the store? Nature Neurosci 1:263–265, 10.1038/1074, 1:CAS:528:DyaK1MXitVCgtbs%3D, 10195155
Basu S, Nagy JA, Pal S et al (2001) The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nature Med 7:569–574, 10.1038/87895, 1:CAS:528:DC%2BD3MXjsVakurY%3D, 11329058
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Asuni, C., Cherchi, A., Congiu, D. et al. Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain 8, 185–189 (2007). https://doi.org/10.1007/s10194-007-0388-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10194-007-0388-5